From the Journals

Age at time of breast cancer diagnosis differs by race/ethnicity


 

FROM JAMA SURGERY

Nonwhite women are significantly more likely than white women to be diagnosed with breast cancer before age 50 years, according to an analysis of Surveillance, Epidemiology, and End Results (SEER) Program data for almost 750,000 women.

“Our finding challenges established norms with regard to screening practices and provides empirical evidence that race-based screening should be considered,” Sahael M. Stapleton, MD, and his associates at Massachusetts General Hospital, Boston, wrote in a research letter published online March 7 by JAMA Surgery.

Women with breast cancer who were diagnosed before age 50
Early breast cancer diagnosis was most common in Hispanic women, with 34.9% of diagnoses occurring before the age of 50 years. The corresponding proportions were 32.8% for Asian women, 31.0% for black women, and 23.6% for white women, they reported.

The researchers charted age at diagnosis and race/ethnicity for the 747,763 women in the SEER database from Jan. 1, 1973, through Dec. 31, 2010; this revealed “two distinct distribution patterns of age at diagnosis for female breast cancers: White patients peak in their 60s, whereas nonwhite patients peak in their 40s,” the investigators wrote.

Their calculations show that “screening ages would need to decrease to 47 years for black, 46 years for Hispanic, and 47 years for Asian patients ... to achieve a similar capture rate for nonwhite patients as current guidelines do for white patients” at 50 years of age.

Dr. Stapleton reported receiving support from two Massachusetts General Hospital fellowships. No other disclosures were reported.

SOURCE: Stapleton SM et al. JAMA Surg. 2018 Mar 7. doi: 10.1001/jamasurg.2018.003.

Recommended Reading

AHA: Heart health helps optimize breast cancer outcomes
Breast Cancer ICYMI
PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer
Breast Cancer ICYMI
Cyclophosphamide extends PFS in elderly HER2+ breast cancer patients
Breast Cancer ICYMI
Exercise during chemotherapy may yield long-term physical benefits
Breast Cancer ICYMI
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
Breast Cancer ICYMI
Measurement of physical activity and sedentary behavior in breast cancer survivors
Breast Cancer ICYMI
Breast cancer deaths projected for 2018
Breast Cancer ICYMI
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
Breast Cancer ICYMI
FDA authorizes first direct-to-consumer BRCA1/2 test
Breast Cancer ICYMI
Breast cancer care delayed when patients have high deductibles
Breast Cancer ICYMI